# OnCo record obrixtamig (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/obrixtamig/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "obrixtamig" ;
  schema:name "Obrixtamig"@en ;
  schema:alternateName "BI 764532"@en, "BI-764532"@en ;
  schema:description "Obrixtamig is an antibody with two arms: one grabs DLL3, a protein on the surface of most neuroendocrine carcinomas, and the other grabs a T cell, pulling the killer cell onto the cancer. It is in a phase 3 trial for neuroendocrine carcinomas outside the lung."@en ;
  schema:url <https://onco.cc/drugs/obrixtamig/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  onco:status "phase-3" ;
  onco:tag "subtype-drugs-wave" ;
  onco:modality "DLL3 x CD3 bispecific T-cell engager" ;
  onco:related <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/peluntamig/>, <https://onco.cc/drugs/zg006/> ;
  onco:cancers <https://onco.cc/cancers/extrapulmonary-nec/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/dll3/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/boehringer-ingelheim/> .